Victory Capital Management
IDXG

Victory Capital Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Victory Capital Management’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,244
Closed -$6K – 3736
2020
Q1 		$6K Buy
+1,244
New +$9.01K ﹤0.01% 3495
2019
Q4 		– Sell
-639
Closed -$5K – 3703
2019
Q3 		$5K Buy
+639
New +$4.99K ﹤0.01% 3484

Other funds holding IDXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Victory Capital Management's IDXG Position: Q2 2020 in Review

Victory Capital Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q2 2020, closing a stake of 1,244 shares — an estimated $6K sold.

Victory Capital Management first reported a position in IDXG in Q3 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2020. 14 funds tracked by Wall St. Rank hold IDXG as of Q2 2020.

  • Victory Capital Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 1,244 Interpace Biosciences, Inc. Common Stock shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Interpace Biosciences, Inc. Common Stock position peaked at $6K in Q1 2020.
  • 14 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.